GHGary Hessman

Gary Hessman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gary Hessman has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid diazotransfer for selective lysine labelling

    by Susannah H. Calvert, Tomasz Pawlak, Gary Hessman, Joanna F. McGouran

    A rapid method to install azides into amino acids, peptides, and proteins, allowing for selective modification of a single lysine.


  • Open Access

    Probing enzymatic activity – a radical approach

    by Neil C. Taylor, Gary Hessman, Holger B. Kramer, Joanna F. McGouran

    Deubiquitinating enzymes (DUBs) are known to have numerous important interactions with the ubiquitin cascade and their dysregulation is associated with several diseases, including cancer and neurodegeneration. They are an important class of enzyme, and activity-based probes have been developed as an effective strategy to study them. Existing activity-based probes that target the active site of these enzymes work via nucleophilic mechanisms. We present the development of latent ubiquitin-based probes that target DUBs via a site selective, photoinitiated radical mechanism. This approach differs from existing photocrosslinking probes as it requires a free active site cysteine. In contrast to existing cysteine reactive probes, control over the timing of the enzyme–probe reaction is possible as the alkene warhead is completely inert under ambient conditions, even upon probe binding. The probe's reactivity has been demonstrated against recombinant DUBs and to capture endogenous DUB activity in cell lysate. This allows more finely resolved investigations of DUBs.


  • Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4‐methylphenmetrazine (4‐MPM), with differentiation from its ortho‐ and meta‐ positional isomers

    by Gavin McLaughlin, Michael H. Baumann, Pierce V. Kavanagh, Noreen Morris, John D. Power, Geraldine Dowling, Brendan Twamley, John O'BRien, Gary Hessman, Folker Westphal, et al.

    The availability of new psychoactive substances on the recreational drug market continues to create challenges for scientists in the forensic, clinical and toxicology fields. Phenmetrazine (3‐methyl‐2‐phenylmorpholine) and an array of its analogs form a class of psychostimulants that are well documented in the patent and scientific literature. The present study reports on two phenmetrazine analogs that have been encountered on the NPS drug market following the introduction of 3‐fluorophenmetrazine (3‐FPM), namely 4‐methylphenmetrazine (4‐MPM) and 3‐methylphenmetrazine (3‐MPM). This study describes the syntheses, analytical characterization and pharmacological evaluation of the positional isomers of MPM. Analytical characterizations employed various chromatographic, spectroscopic and mass spectrometric platforms. Pharmacological studies were conducted in order to assess whether MPM isomers might display stimulant‐like effects similar to the parent compound phenmetrazine. The isomers were tested for their ability to inhibit uptake or stimulate release of tritiated substrates at dopamine, norepinephrine and serotonin transporters using in vitro transporter assays in rat brain synaptosomes. The analytical characterization of three vendor samples revealed the presence of 4‐MPM in two of the samples and 3‐MPM in the third sample, which agreed with the product label. The pharmacological findings suggest that 2‐MPM and 3‐MPM will exhibit stimulant properties similar to the parent compound phenmetrazine, whereas 4‐MPM may display entactogen properties more similar to MDMA. The combination of test purchases, analytical characterization, targeted organic synthesis and pharmacological evaluation of NPS and their isomers is an effective approach for the provision of data on these substances as they emerge in the marketplace.


  • Synthesis, characterisation and DNA intercalation studies of regioisomers of ruthenium (II) polypyridyl complexes

    by Laura Perdisatt, Samar Moqadasi, Luke O'NEill, Gary Hessman, Alessandra Ghion, Muhammad Qasim Mushtaq Warraich, Alan Casey, Christine O'COnnor


  • An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: The microscale syntheses of nitrazolam and clonazolam for use as reference materials, utilizing polymer‐supported reagents

    by Geraldine Dowling, Pierce V. Kavanagh, Hans‐Georg Eckhardt, Brendan Twamley, Gary Hessman, Gavin McLaughlin, John O'BRien, Simon D. Brandt

    Nitrazolam and clonazolam are 2 designer benzodiazepines available from Internet retailers. There is growing evidence suggesting that such compounds have the potential to cause severe adverse events. Information about tolerability in humans is scarce but typically, low doses can be difficult to administer for users when handling bulk material. Variability of the active ingredient in tablet formulations can also be of a concern. Customs, toxicology and forensic laboratories are increasingly encountering designer benzodiazepines, both in tablet and powdered form. The unavailability of reference standards can impact on the ability to identify these compounds. Therefore, the need arises for exploring in‐house approaches to the preparation of new psychoactive substances (NPS) that can be carried out in a timely manner. The present study was triggered when samples of clonazolam were received in powdered and tablet form at a time when reference material for this drug was commercially unavailable. Therefore, microscale syntheses of clonazolam and its deschloro analog nitrazolam were developed utilizing polymer‐supported reagents starting from 2‐amino‐2'‐chloro‐5‐nitrobenzophenone (clonazolam) and 2‐amino‐5‐nitrobenzophenone (nitrazolam). The final reaction step forming the 1,2,4‐triazole ring moiety was performed within a gas chromatography–mass spectrometry (GC–MS) injector. A comparison with a preparative scale synthesis of both benzodiazepine derivatives showed that microscale synthesis might be an attractive option for a forensic laboratory in terms of time and cost savings when compared with traditional methods of synthesis and when qualitative identifications are needed to direct forensic casework. The reaction by‐product profiles for both the micro and the preparative scale syntheses are also presented.


  • Analytical characterization and pharmacological evaluation of the new psychoactive substance 4‐fluoromethylphenidate (4F‐MPH) and differentiation between the (±)‐threoand (±)‐erythrodiastereomers

    by Gavin McLaughlin, Noreen Morris, Pierce V. Kavanagh, John D. Power, Geraldine Dowling, Brendan Twamley, John O'BRien, Gary Hessman, Brian Murphy, Donna Walther, et al.

    Misuse of (±)‐threo‐methylphenidate (methyl‐2‐phenyl‐2‐(piperidin‐2‐yl)acetate; Ritalin®; MPH) has long been acknowledged, but the appearance of MPH analogs in the form of ‘research chemicals’ has only emerged in more recent years. 4‐Fluoromethylphenidate (4F‐MPH) is one of these recent examples. This study presents the identification and analytical characterization of two powdered 4F‐MPH products that were obtained from an online vendor in 2015. Interestingly, the products appeared to have originated from two distinct batches given that one product consisted of (±)‐threo‐4F‐MPH isomers whereas the second sample consisted of a mixture of (±)‐threoand (±)‐erythro4F‐MPH. Monoamine transporter studies using rat brain synaptosomes revealed that the biological activity of the 4F‐MPH mixture resided with the (±)‐threoand not the (±)‐erythroisomers based on higher potencies determined for blockage of dopamine uptake (IC504F‐MPHmixture = 66 nM vs. IC50(±)‐threo = 61 nM vs. IC50(±)‐erythro = 8,528 nM) and norepinephrine uptake (IC504F‐MPHmixture = 45 nM vs. (±)‐threo = 31 nM vs. IC50(±)‐erythro = 3,779 nM). In comparison, MPH was three times less potent than (±)‐threo‐4F‐MPH at the dopamine transporter (IC50 = 131 nM) and around 2.5 times less potent at the norepinephrine transporter (IC50 = 83 nM). Both substances were catecholamine selective with IC50values of 8,805 nM and >10,000 nM for (±)‐threo‐4F‐MPH and MPH at the serotonin transporter. These findings suggest that the psychostimulant properties of (±)‐threo‐4F‐MPH might be more potent in humans than MPH. Copyright © 2017 John Wiley & Sons, Ltd.


  • Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL‐40,940 and CRL‐40,941 in the GC injector: formation of 1,1,2,2‐tetraphenylethane and its tetra fluoro analog

    by Geraldine Dowling, Pierce V. Kavanagh, Brian Talbot, John O’bRien, Gary Hessman, Gavin McLaughlin, Brendan Twamley, Simon D. Brandt

    2‐[(Diphenylmethyl)sulfinyl]acetamide (modafinil) is commonly prescribed for the treatment of narcolepsy. Increasing popularity and off‐label use as a cognitive enhancer has resulted in a reputation as an intelligence boosting ‘wonder drug'. Common alternatives available from online shops and other retail outlets include 2‐[(diphenylmethyl)sulfinyl]‐N‐hydroxyacetamide (adrafinil), 2‐{[bis(4‐fluorophenyl)methyl]sulfinyl}acetamide (CRL‐40,940), 2‐{[bis(4‐fluorophenyl)methyl]sulfinyl}‐N‐hydroxyacetamide (CRL‐40,941), and N‐methyl‐4,4‐difluoro‐modafinil (modafiendz), respectively. Gas chromatography‐mass spectrometry (GC‐MS) is a common tool used in forensic and clinical analysis but there is a potential for inducing analysis‐related ambiguities. This study reports on the thermal degradation of modafinil, modafinic acid, adrafinil, CRL‐40,940, and CRL‐40,941 due to exposure to the heated GC injection port dissolved in a variety of solvents. Key degradation products common to modafinil, modafinic acid, and adrafinil analysis included diphenylmethanol and 1,1,2,2‐tetraphenylethane (TPE), the latter of which was verified by its synthesis and characterization by x‐ray crystallography. The investigated compounds were also characterized by 1H and 13C NMR. Diphenylmethane and thiobenzophenone were also identified in some instances. TPE formation was suggested to involve the generation of a benzhydrylium ion and its reaction with the sulfoxide oxygen of the parent compound to give an oxysulfonium intermediate. Correspondingly, the fluorinated TPE analogue was formed during heat‐induced degradation of modafiendz, CRL‐40,940 and CRL‐40,941, respectively. When a mixture of modafinil (non‐fluorinated) and modafiendz (fluorinated) were subjected to GC analysis, 4,4'‐(2,2‐diphenylethane‐1,1‐diyl)bis(fluorobenzene) was detected as a third cross reaction product in addition to the two expected TPE analogues. These observations served as a reminder that the seemingly straightforward implementation of GC‐MS analysis can lead to challenges during routine analysis.


  • Formation of Self‐Templated 2,6‐Bis(1,2,3‐triazol‐4‐yl)pyridine [2]Catenanes by Triazolyl Hydrogen Bonding: Selective Anion Hosts for Phosphate

    by Joseph P. Byrne, Salvador Blasco, Anna B. Aletti, Gary Hessman, Thorfinnur Gunnlaugsson

    We report the remarkable ability of 2,6‐bis(1,2,3‐triazol‐4‐yl)pyridine (btp) compounds 2 with appended olefin amide arms to self‐template the formation of interlocked [2]catenane structures 3 in up to 50 % yield when subjected to olefin ring‐closing metathesis in CH2Cl2. X‐ray diffraction crystallography enabled the structural characterization of both the [2]catenane 3 a and the non‐interlocked macrocycle 4 a. These [2]catenanes showed selective triazolyl hydrogen‐bonding interactions with the tetrahedral phosphate anion when screened against a range of ions; 3 a,b are the first examples of selective [2]catenane hosts for phosphate.


  • Formation of Self‐Templated 2,6‐Bis(1,2,3‐triazol‐4‐yl)pyridine [2]Catenanes by Triazolyl Hydrogen Bonding: Selective Anion Hosts for Phosphate

    by Joseph P. Byrne, Salvador Blasco, Anna B. Aletti, Gary Hessman, Thorfinnur Gunnlaugsson

    We report the remarkable ability of 2,6‐bis(1,2,3‐triazol‐4‐yl)pyridine (btp) compounds 2 with appended olefin amide arms to self‐template the formation of interlocked [2]catenane structures 3 in up to 50 % yield when subjected to olefin ring‐closing metathesis in CH2Cl2. X‐ray diffraction crystallography enabled the structural characterization of both the [2]catenane 3 a and the non‐interlocked macrocycle 4 a. These [2]catenanes showed selective triazolyl hydrogen‐bonding interactions with the tetrahedral phosphate anion when screened against a range of ions; 3 a,b are the first examples of selective [2]catenane hosts for phosphate.